Zapping away AFib: first human test of new ablation device begins
NCT ID NCT06452589
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new device called the FieldForce Ablation System in 35 people with atrial fibrillation (AFib). The device uses short electrical pulses to destroy tiny areas of heart tissue causing the irregular rhythm. The main goals are to see if it is safe and if it can successfully isolate the pulmonary veins, a key step in treating AFib.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- FieldForce Ablation System (pulsed field ablation device)
- What this could lead to
- If successful, this could provide a new, safer option for treating atrial fibrillation by using targeted electrical pulses to correct heart rhythm.
- What could go wrong
- This is a very early, first-in-human trial with only 35 people. The device may not work as expected or could cause side effects like heart rhythm problems or blood clots.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
35 people
The number who actually took part.
- Started
-
Jul 2024
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Signed patient informed consent form (ICF). 2. Female and male patients aged ≥ 18 and ≤ 80. 3. Documented atrial fibrillation via an electrocardiogram (must be at least 30 seconds) within one year of enrollment. 4. Indicated for a first-time catheter ablation for atrial fibrillation or associated atrial arrhythmias (European guidelines). Exclusion Criteria: 1. Body Mass Index \> 40. 2. Ineligible for ablation (including but not limited to known left atrial thrombus). 3. AF secondary to electrolyte imbalance, thyroid disease, alcohol abuse or other reversible/non-cardiac causes. 4. Previous endocardial/epicardial ablation or surgery for AF. 5. NYHA Class IV. 6. Left atrial appendage device or occlusion within 180 days. 7. Atrial or ventricular septal defect closure. 8. Atrial myxoma. 9. The presence of inferior vena cava embolic protection filter devices. 10. Significant or symptomatic untreated hypotension, bradycardia, or chronotropic incompetence. 11. History of hemodynamically severe valvular disease. Severity should be assessed using echocardiography, according to AHA and European guidelines. 12. Diagnosis of pacemaker dependance. 13. Uncontrolled abnormal bleeding and/or clotting disorder. 14. Contraindication to systemic or oral anticoagulation. 15. Serious or untreated medical conditions that would prevent participation in the study, interfere with assessment of therapy, or confound data or its interpretation, including but not limited to solid organ or hematologic transplant, or currently being evaluated for an organ transplant. 16. History of severe lung disease, pulmonary hypertension, or any lung disease involving abnormal blood gases or significant dyspnea which may interfere with the assessment of the therapy. 17. Active malignancy. 18. Uncontrolled clinically significant infection. 19. Life expectancy is less than one year. 20. Clinically significant psychological condition that in the investigator's opinion would prohibit the subject's ability to meet the study requirements. 21. Any of the following within 3 months of enrollment: myocardial infarction, unstable angina, percutaneous coronary intervention, heart surgery (coronary artery bypass grafting/atriotomy), stroke or transient ischemic attack (TIA); 22. Participation in another investigational study that would interfere with this study. 23. Patient is not able to understand the nature of this study or is unwilling or unable to attend the study procedures. 24. Women who are of childbearing age and not on a reliable form of birth control.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atrial arrhythmias are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Na Homolce Hospital
Prague, 150 00, Czechia
More trials for these conditions
Other studies related to the condition(s) this trial covers.